Acylated active agents and methods of their use for the treatment of autoimmune disorders
Steven John Taylor, Winchester, MA (US); Mi-Jeong Kim, Boston, MA (US); Kathleen Nudel, Jamaica Plain, MA (US); Timothy F. Briggs, Waltham, MA (US); Koji Yasuda, Boston, MA (US); Leonard Buckbinder, East Greenwich, RI (US); Bernard Lanter, Somerville, MA (US); Spencer Cory Peck, Watertown, MA (US); Cheri Snedeker, Boston, MA (US); Angela She, Cambridge, MA (US); Jessica Alexander, Waltham, MA (US); Anna Liang, Everett, MA (US); Jenny Liu, Cambridge, MA (US); Dinara Gunasekera, Cambridge, MA (US); David Arthur Berry, Waban, MA (US); John Patrick Casey, Jr., Boston, MA (US); and Amir H. Moarefi, Encino, CA (US)
Assigned to Flagship Pioneering Innovations V, Inc., Cambridge, MA (US)
Filed by Flagship Pioneering Innovations V, Inc., Cambridge, MA (US)
Filed on Dec. 21, 2021, as Appl. No. 17/557,772.
Application 17/557,772 is a division of application No. 17/319,285, filed on May 13, 2021, abandoned.
Application 17/319,285 is a continuation of application No. 16/803,284, filed on Feb. 27, 2020, granted, now 11,058,698, issued on Jul. 13, 2021.
Application 16/803,284 is a continuation of application No. PCT/US2019/035677, filed on Jun. 5, 2019.
Claims priority of provisional application 62/776,377, filed on Dec. 6, 2018.
Claims priority of provisional application 62/680,965, filed on Jun. 5, 2018.
Prior Publication US 2022/0110960 A1, Apr. 14, 2022
1. A method of modulating an autoimmunity marker in a subject, the method comprising administering to the subject an effective amount of a compound of the structure:
